BiomX Inc (PHGE)

Apr 28, 2025

Short Interest in BiomX Inc. (NYSEAMERICAN:PHGE) Decreases By 48.2% - Defense World

Apr 28, 2025

Apr 19, 2025

BiomX (PHGE) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - MSN

Apr 19, 2025

Apr 06, 2025

HC Wainwright Reiterates “Buy” Rating for BiomX (NYSEMKT:PHGE) - Defense World

Apr 06, 2025

Apr 04, 2025

Q1 Earnings Estimate for BiomX Issued By HC Wainwright - Defense World

Apr 04, 2025

Apr 04, 2025

What is HC Wainwright’s Estimate for BiomX FY2025 Earnings? - Defense World

Apr 04, 2025

Apr 03, 2025

What is HC Wainwright’s Forecast for BiomX Q1 Earnings? - Defense World

Apr 03, 2025

Apr 02, 2025

HC Wainwright Issues Positive Forecast for BiomX (NYSEAMERICAN:PHGE) Stock Price - Defense World

Apr 02, 2025

Apr 02, 2025

Earnings call transcript: Biomx Q1 2025 sees potential breakthrough in phage therapy By Investing.com - Investing.com South Africa

Apr 02, 2025

Apr 01, 2025

Earnings call transcript: Biomx Q1 2025 sees potential breakthrough in phage therapy - Investing.com India

Apr 01, 2025

Apr 01, 2025

Biomx stock plunges to 52-week low, hits $0.48 - Investing.com

Apr 01, 2025

Apr 01, 2025

Biomx stock plunges to 52-week low, hits $0.48 By Investing.com - Investing.com India

Apr 01, 2025

Apr 01, 2025

BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure - GlobeNewswire

Apr 01, 2025

Apr 01, 2025

BiomX stock target soars to $21 on Phase 2 trial success - Investing.com India

Apr 01, 2025

Mar 31, 2025

BiomX Announces Positive Phase 2 Trial Results - TipRanks

Mar 31, 2025

Mar 31, 2025

BiomX reports progress in diabetic ulcer treatment By Investing.com - Investing.com Australia

Mar 31, 2025

Mar 31, 2025

BiomX reports progress in diabetic ulcer treatment - Investing.com India

Mar 31, 2025

Mar 31, 2025

BiomX Announces Positive Topline Results From Phase 2 Trial Evaluating Bx211 For The Treatment Of Diabetic Foot Osteomyelitis (DFO) - MarketScreener

Mar 31, 2025

Mar 31, 2025

BiomX Announces Positive Topline Results from Phase 2 Trial - GlobeNewswire

Mar 31, 2025

Mar 31, 2025

Major Clinical Success: BiomX's New Drug Shows Promise in Preventing Diabetic Amputations - Stock Titan

Mar 31, 2025

Mar 27, 2025

Phage Therapy Market Know the Scope and Trends - openPR

Mar 27, 2025

Mar 26, 2025

BiomX (PHGE) Expected to Announce Earnings on Wednesday - Defense World

Mar 26, 2025

Mar 25, 2025

BiomX Inc Reports Q4 2024 EPS of -$2.56, Revenue at $0.00 Millio - GuruFocus

Mar 25, 2025

Mar 25, 2025

BiomX Inc. Secures $12 Million in Financing to Advance Clinical Trials for BX004 and BX211 - Nasdaq

Mar 25, 2025

Mar 25, 2025

BiomX Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business and Program Updates - GlobeNewswire

Mar 25, 2025

Mar 25, 2025

Earnings Scheduled For March 25, 2025 - Benzinga

Mar 25, 2025

Mar 20, 2025

BiomX (PHGE) Expected to Announce Quarterly Earnings on Tuesday - Defense World

Mar 20, 2025

Mar 19, 2025

BiomX to Report Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025 - GlobeNewswire

Mar 19, 2025

Mar 19, 2025

BiomX Inc. to Report Q4 and Full Year 2024 Financial Results on March 25, 2025 - Nasdaq

Mar 19, 2025

Mar 09, 2025

BiomX’s $12 Million Financing - Global Legal Chronicle

Mar 09, 2025

Mar 05, 2025

BiomX Inc. secures $12 million from recent offerings - Investing.com India

Mar 05, 2025

Mar 04, 2025

Biomx raises $12M to advance phage therapy for CF infections - Cystic Fibrosis News Today

Mar 04, 2025

Feb 27, 2025

BiomX Announces $12M Funding for BX004 Study - TipRanks

Feb 27, 2025

Feb 26, 2025

BiomX announces series of financings for aggregate gross proceeds of $12M - MSN

Feb 26, 2025

Feb 26, 2025

BiomX Announces a Series of Financings for Aggregate Gross Proceeds of $12 Million - GlobeNewswire

Feb 26, 2025

Feb 26, 2025

Can BiomX's $12M Financing Push Its Cystic Fibrosis Treatment to the Finish Line? - StockTitan

Feb 26, 2025